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Infection with HIV-1 results in a disruption of the thymic microenvironment and the presence of HIV-1 in thymic epithelial
cells has been demonstrated in vivo. In the present study, we examined the susceptibility of a highly enriched culture of
thymic epithelial cells (TEC) to infection in vitro by HIV-1 laboratory strains and primary isolates. Replication in TEC is shown
to depend on the virus and on the expression of CD4 molecules that are found to be expressed at a low density on the
plasma membrane. Our results are consistent with infection of TEC controlled by the efficiency of the interactions between
the envelope glycoprotein of the virus and the cell surface molecules. As a consequence, certain HIV-1 viruses induce a
productive and persistent infection in TEC without damaging the cells. Altogether these results support the idea that TEC
may act as a reservoir for HIV-1 in the thymus but are probably destroyed by an indirect mechanism involving infection of
thymocytes. q 1996 Academic Press, Inc.
The early invasion and spread of HIV-1 in lymphoid HIV-1 in primary human TEC in vitro. Human TEC cultures
were derived from fresh normal thymic fragments ob-tissues are considered to play a central role in AIDS
pathogenesis (1). They probably contribute to the persis- tained from children undergoing partial thymectomy dur-
ing cardiac surgery. Thymic explants were cultured undertent and rapid turnover of virions (2, 3) that leads to
the progressive disappearance of CD4/ T cells through selective conditions for preferential growth of TEC and
elimination of other thymic accessory cells accordingdirect and indirect pathways. In neonates, the thymus,
which is the site of intensive T-cell development, was to a slightly modified explant technique (14). They were
maintained in McCoy’s medium supplemented with 10%suggested to be the first target for HIV-1. It is thus tempt-
ing to speculate that the rapid progression of AIDS ob- FCS, 2 mM L-glutamine, and antibiotics (PSN, Gibco) in
the presence of 0.5 mg/ml hydrocortisone, 5 1 1009 Mserved in a small proportion of neonates probably in-
fected in utero (4) is related to an early invasion and cholera toxin, 20 ng/ml epidermal growth factor (EGF),
and 5 1 1005 M b-mercaptoethanol. Fifteen days later,severe damages of fetal thymus by HIV-1 (5, 6). The
mechanisms responsible for thymic damages in HIV-1 the explants were removed and the adherent cells were
trypsinized to obtain a confluent monolayer of highly en-infection are not totally clear. HIV infects mature and
immature thymocytes (7, 8) and may induce cell death riched TEC. More than 95% of the cells were cytokeratin-
positive as assessed by immunostaining using KL1 andin multiple populations of thymocytes either directly after
infection or indirectly after perturbation of stromal cells. BT571 antibodies (Immunotech and BioChemical Tech-
nology Inc., respectively) on cells permeabilized by ace-Alterations of the thymic microenvironment were de-
scribed in SIVmac-infected monkeys (9) and in HIV-1- tone– methanol treatment. They also reacted with L191, a
monoclonal antibody (mAb) originally developed againstinfected SCIDhu mice (10) but direct infection of thymic
epithelial cells (TEC) and HIV-1 mediated damage of thy- subcapsular and medullary epithelium (15). In contrast,
our TEC cultures were negative for surface expressionmic epithelium (11– 13) remain controversial.
Here we report differential replicative capacities for of the T-cell markers CD2 (IOT 11) and CD4 (Q4120,
OKT4a, OKT4, Leu3a) and the monocyte/macrophage
marker CD14 (Leu M3) as determined by indirect immu-
nofluorescence and flow cytometry. HLA-DR (IOT2b) and1 Present address: UMR30, Immuno-Virologie Mole´culaire et cellu-
laire, Faculte´ de Me´decine Alexis Carrel, Rue Guillaume Paradin, 69372 CD18 (M232) were constitutively expressed as were the
Lyon Cedex 08, France.
adhesion molecules CD54 (IOL54), CD58 (IOL58), and2 To whom reprint requests should be addressed at De´partement de
CD59 (P296R). In functional terms, we also found that ourVirologie, Unite´ de Biologie des Re´trovirus, Institut Pasteur, 25, Rue du
Dr. Roux, 75724 Paris Cedex 15, France. Fax: 33 (1) 45 68 89 57. TEC cultures were able to interact with human allogenic
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FIG. 1. Replication of HIV-1/LAI and HIV/NDK in primary cultures of human TEC. (A) Subconfluent TEC (1.6 1 104 cells/cm2) were exposed to
HIV-1/NDK or HIV/LAI for 1 hr at 377. After extensive washings, the cells were maintained in the selective tissue culture medium and were subcultured
at confluence. Culture supernatants were collected every 3 or 4 days after infection and analyzed for virus production by measuring reverse
transcriptase (RT) activity (35). The doses of virus used for infection were 0.01 mg p24 Ag/106 cells (- -l--) and 0.1 mg p24 Ag/106 cells ( — l — )
for HIV-1/NDK and 0.3 mg p24 Ag/106 cells ( — j —) for HIV-1/LAI. (B) In order to detect a low level of infectious virions in TEC infected by HIV-
1/LAI, a cell lysate was prepared by successive freezings and thawings; it was obtained from a TEC culture infected by 0.3 mg HIV-1/LAI p24 Ag/
106 cells and collected 15 days postinfection when no residual p24 Ag was detected in the culture supernatant. This TEC lysate was used as
inoculum (j) to infect stimulated human PBMC as previously described (8). As controls, lysates from noninfected TEC (n) and from intestinal
epithelial CaCo2 cells infected with a similar dose of HIV-1/LAI (m) were used as inocula for human PBMC. Virus production in PBMC supernatants
was assessed by measuring RT activity. The horizontal lines indicate the background of our RT assay. (C) Neutralization of HIV-1 replication in TEC
by CD4 mAbs. TEC cultures treated or not for 1 hr with 20 mg/ml of mAbs directed to the D1 domain of CD4. They were then exposed to 0.01 mg
HIV-1/NDK p24 Ag/106 cells (dotted lines) or to 5 mg HIV-1/LAI p24 Ag/106 cells (solid lines). They were then cultured for 13 days in medium alone
(j) or in the presence of CD4 mAb Q4120 (h), OKT4a (l), or IOT4a (m) at 2 mg/ml. The cells were then collected and after extensive washings,
TEC lysates were prepared and used as inocula to infect human PBMC as indicated above.
thymocytes as indicated by rosette formation (data not to 55 days after exposure to HIV-1/NDK. No necrosis,
apoptosis, or syncitium formation was observed and theshown).
These phenotypically and functionally characterized proliferation of the cells was identical as in noninfected
TEC cultures (data not shown). After infection by HIV-1/TEC cultures were then examined for their capacity to
support HIV-1 infection in vitro. Two HIV-1 laboratory LAI no release of virions was observed as assessed by
the lack of detectable RT activity (Fig. 1A) and p24 Ag instrains (HIV-1/LAI and HIV-1/NDK) previously reported to
vary in their host range for CD4-positive and -negative TEC supernatants. These observations were consistent
with electron microscopy (EM) studies that show viralcells (16, 17) were first tested. Distinct patterns of viral
replication were observed after infection in vitro (Fig. 1A). budding at the cell surface or on intracellular invagi-
nations, confirming an active replication of HIV-1/NDK inInfection of TEC by HIV-1/NDK was highly productive as
indicated by the significant RT activity detected in cell- TEC (Fig. 2). Mature or immature particles were mostly
localized at one pole of the cells or within cellular invagi-free supernatants by Day 11 for the highest dose of virus
and by Day 22 for the lowest one. A high level of p24 nations. These pictures of HIV-1 associated with TEC
within vacuole-like structures were previously describedantigen (p24 Ag) was observed 1 week earlier than RT
activity (data not shown). The infection was persistent as in the SCIDhu mouse model (12) but without any clear
evidence of budding particles. None of these structuresindicated by the continuous production of virus for up
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FIG. 2. Detection of HIV-1 particles in TEC by electron microscopy on Day 23 after infection by HIV-1/NDK (1 mg p24 Ag/106 cells). Confluent
monolayers of TEC in 25-cm2 flasks were fixed with 1.6% glutaraldehyde in 0.1 M phosphate buffer, pH 7.3. They were then washed in phosphate
buffer, fixed in 1% buffered OsO4 , dehydrated with an alcohol series, and embedded in epoxy resin in situ. Thin sections were counterstained with
uranyl acetate and lead citrate. Mature and immature virions were observed either outside the cell or inside pouches (p) (a). Some virions are
trapped in microvillar extensions on the surface of the cell (a; arrowhead). Active budding of particles (thin arrows) was also seen at the surface
of TEC (b). Magnification (a) 135,000; (b) 160,000.
were observed in TEC cultures infected by HIV-1/LAI. 1/IIIB inoculum was produced in H9 cells rather than
CEM for HIV-1/LAI. Although we did not demonstrate aTogether with the absence of p24 Ag in cell-free superna-
tants, these observations indicated that HIV-1/LAI is transient production of HIV-1/LAI after in vitro infection
of TEC, we could not definitively exclude a low level ofpoorly infectious for TEC compared to HIV-1/NDK. Our
data diverge from the transient productive infection of HIV-1/LAI replication in those cells.
To address this question, human peripheral blood mo-TEC previously reported (11). This may be related to dif-
ferences in experimental conditions; in particular, Numa- nonuclear cells (PBMC) were used as sensitive indicator
cells to detect a low level of replicating HIV-1/LAI in TEC.zaki et al. used HIV-1/IIIB, a strain genetically distinct
from HIV-1/NDK but identical to HIV-1/LAI (18). Their HIV- As shown in Fig. 1B, a significant RT activity was detected
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in PBMC cultures exposed to a lysate of HIV-1/LAI in- ing CD4-negative cells (20). We thus suspected a low
expression of CD4 molecules on our TEC that could cor-fected TEC. Similar results were obtained when infected
TEC were cocultured with human PBMC (data not relate with a low efficiency of HIV-1/LAI infectivity for
those cells as already reported for primary isolates (21)shown), demonstrating the presence of infectious virions
in TEC. Cell lysates or cultures of infected TEC were used and for other cells as well (8, 22). The expression of
CD4 mRNA into TEC that we found by polymerase chainas inocula for PBMC as late as 15 days after infection by
HIV-1/LAI. Viral particles nonspecifically adsorbed on or reaction (PCR) after reverse transcription (data not
shown) supported this idea. To establish a CD4 depen-trapped within TEC are thus unlikely to be responsible
for the infection of PBMC. In addition, no infectious virus dence for viral infectivity on TEC, we tested whether a
panel of CD4 mAbs would block their infection by HIV-could be detected in control experiments using our
PBMC assays with another human epithelial cell, the 1/LAI and HIV-1/NDK. We found that mAbs directed to the
D1 domain of CD4 (Q4120, OKT4a, and IOT4a) completelycolon carcinoma cell line CaCo2 that is described as
being unable to support HIV-1/LAI replication in vitro (19). prevented the infection by HIV-1/LAI as demonstrated by
PCR analysis of HIV-1 DNA in TEC and by our assay onTo further determine whether the infectious virions de-
tected by our PBMC assays were from newly initiated human PBMC (Fig. 1C). The infection of TEC by HIV-1/
NDK was entirely neutralized by the D1 mAb (Q4120),viral synthesis in TEC, TEC cultures were infected by
HIV-1/LAI in the presence of 40 mM reverse transcriptase which reacts with the high-affinity binding site for gp120,
the outer envelope glycoprotein of HIV-1 (23). However,inhibitor AZT. The infectivity of TEC inocula for PBMC
was entirely abrogated by AZT treatment (data not unlike HIV-1/LAI, HIV-1/NDK infection was not blocked
by the two other D1 mAbs (OKT4a and IOT4a), as indi-shown). This result strongly suggests that the virions
taken up by PBMC were not adsorbed or trapped within cated by our assay on human PBMC (Fig. 1C). Thus, our
data demonstrate that viral binding to the CD4 receptorTEC but most likely initiated a restricted but active repli-
cation of HIV-1/LAI in TEC. They provide evidence that is required for infection of TEC by both HIV-1/LAI and
HIV-1/NDK. They are consistent with the previous reportHIV-1/LAI, like HIV-1/NDK, enters and replicates in TEC,
albeit at a lower efficiency. To further analyze the level on the CD4-dependent entry of HIV-1/IIIB into TEC (11)
but contrast with the CD4-independent entry of HIV-1/of expression of HIV-1/LAI and HIV-1/NDK into TEC, in
situ hybridization (ISH) was performed on cells infected NDK into intestinal epithelial cells (20). In fact, we found
a relative resistance of HIV-1/NDK to neutralization byby similar doses of virus at a time when p24 Ag produc-
tion was optimal in TEC cultures infected by HIV-1/NDK. CD4 mAbs to D1 as previously described for CD4/ T
cells (16); this may be related to its enhanced infectivityAs shown in Fig. 3, a high level of viral mRNA was ex-
pressed at that time in HIV-1/NDK-infected TEC as as- for TEC. This resistance suggested that its efficient repli-
cation in TEC may be due to specific HIV-1/NDK envsessed by the number of grains observed in each in-
fected cell. A relatively high proportion of TEC was ex- sequences, which have been implicated in its wide host
cell tropism for CD4-positive and -negative cells in vitropressing HIV-1/NDK mRNA at that time, but even when
a high infectious dose of virus was used, the percentage (24). The replication pattern observed for HIV-1/NDK on
TEC would, therefore, not be expected to resemble thatof positive cells was never higher than 30%. Our result
indicates that only a subpopulation of TEC is sensitive of other viruses, in particular primary isolates. Further
infection experiments were thus carried out on TEC usingto HIV-1/NDK. This may be explained by the heterogene-
ity of our TEC, which are probably derived from both identical doses of virus to compare HIV-1/LAI and HIV-
1/NDK with four primary isolates from Caucasian andthymic cortex and medulla (15). Whether HIV-1/NDK repli-
cates preferentially in cortical or medullary epithelial African patients. One African isolate (HIV-1/4039)
showed a replication kinetic on TEC similar to that of HIV-cells remains to be determined. However, according to
the cell markers of our cultures and to the proportion of 1/NDK (data not shown), demonstrating that a productive
infection of TEC by primary isolates can be established.cells which are positive by ISH, it is clear that the replica-
tion occurred in TEC and not in any contaminating non- No virus production was detected in TEC cultures after
infection by the three other HIV-1 isolates but, in contrastepithelial cells. In contrast to TEC cultures infected by
HIV-1/NDK, no viral mRNA could be detected in HIV-1/ to HIV-1/LAI, we did not even detect low-level replication
in TEC in our assay on human PBMC (data not shown).LAI-infected cells (data not shown), confirming the low
replicative capacity of HIV-1/LAI in TEC. This low level Overall, these results provide evidence for a distinct
host range tropism of HIV-1 isolates for TEC. It mostof replication may be due to the inefficient entry of HIV-
1/LAI into our TEC cultures, which showed no detectable likely involves viral determinants in the env gene. In-
deed, our preliminary observation that chimeric HIV-1/CD4 molecules at their surface by immunohistochemistry
or flow cytometry. LAI expressing HIV-1/NDK env replicates as efficiently
in TEC as HIV-1/NDK (data not shown) supports thisAs far as we know, the entry of HIV-1/LAI into target
cells requires its binding to the CD4 receptor. In contrast, idea. Although the env regions involved remain to be
determined, it should be noted that we did not observeit has been reported that HIV-1/NDK is capable of enter-
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FIG. 3. Expression of viral mRNA in HIV-1/NDK infected TEC by ISH. Primary cultures of TEC were infected by HIV-1/NDK (1 mg p24 Ag/106 cells)
and 46 days later the cells were trypsinized and fixed on glass slides. ISH was carried out using a 35S-UTP-labeled gag/pol HIV-1 riboprobe as
previously described (8, 36). Magnification, 1250. All the controls performed on noninfected TEC or on HIV-1/NDK-infected cells using a HIV-1 RNA
probe in a sense orientation were negative, demonstrating the specificity of the signals observed by ISH (data not shown).
any correlation between the V3 subtype and phenotype ACKNOWLEDGMENTS
of the virus used for infection and its infectivity poten-
We are very grateful to Professor F. Leca (Paris, France) for providing
tial for TEC. In fact, the fusogenic phenotype of HIV- us thymus from infants undergoing cardiac surgery. Some mAbs were
1/NDK (25) and its reduced sensitivity to CD4 mAb generously donated by Dr. Q. Sattentau (Marseille, France) for Q4120,
by Dr. L. Boumsell (Paris, France) for P296R and by Professor A. Bernardneutralization described above indicate that env re-
(Nice, France) for M232 and L191. The primary isolates HIV-1/732 andgions interacting with CD4 (26) and/or with secondary
HIV-1/EKE were from Professor H. Agut (Paris, France) and HIV-1/BXO8cell surface coreceptors such as those recently re-
from Professor H. Fleury (Bordeaux, France). We particularly thank Dr.
ported (27– 29) could be implicated in the infectivity for L. Boumsell and Dr. A. Rein (Frederick, MD) for helpful discussions
TEC. Further studies with chimeric viruses may provide and critical comments, Dr. A. Dalloul and Professor P. Debre´ for their
advice, P. Versmisse for his excellent technical assistance, and B.insight concerning the env determinants involved in
Lacroix for her help. This work was supported by ANRS and FRMthe viral tropism for TEC and also on the role of other
through grants and fellowships.genes known to influence host range tropism (30) and
replication in vitro and in vivo (31, 32). One important
REFERENCESaspect of our study is the demonstration that certain
HIV-1 variants can induce a productive and persistent 1. Fauci, A. S., Science 262, 1011– 1018 (1993).
2. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M.,infection of TEC without any cell degeneration, sup-
and Markowitz, M., Nature 373, 123– 126 (1995).porting the idea of their potential role as reservoir for
3. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A.,dissemination of virus into maturating thymocytes. This
Deutsch, P., Lifson, J. D., Bonhoefer, S., Nowak, M. A., Hahn,
finding also implies that the damage of the epithelial B. H., Saag, M. S., and Shaw, G. M., Nature 373, 117–122 (1995).
network observed in vivo (12, 13) is not directly related 4. Courgnaud, V., Laure´, F., Brossard, A., Bignozzi, C., Goudeau, A.,
Barin, F., and Bre´chot, C., AIDS Res. Hum. Retrovirus 7, 337–to the infection of TEC. Survival of TEC requires signals
341 (1991).provided by developing thymocytes (33, 34). We there-
5. Papiernik, M., Brossard, Y., Mulliez, N., Roume, J., Brechot, C., Barin,fore propose that the infection of thymocytes is proba-
F., Goudeau, A., Bach, J.-F., Griscelli, C., Henrion, R., and Vazeux,
bly playing a crucial role in TEC degeneration through R., Pediatrics 89, 297– 301 (1992).
induction of cell death or abnormal signaling between 6. Jovaisas, E., Koch, M. A., Scha¨fer, A., Stauber, M., and Lo¨wenthal,
D., Lancet 2, 1129 (1985). [Letter]thymocytes and stromal cells.
AID VY 8211 / 6a21$$$462 10-18-96 13:02:34 vira AP: Virology
418 SHORT COMMUNICATION
7. Schnittman, S. M., Denning, S. M., Greenhouse, J. J., Justement, 22. Su, L., Kaneshima, H., Bonyhadi, M., Salimi, S., Kraft, D., Rabin, L.,
and McCune, J. M., Immunity 2, 25 –36 (1995).J. S., Baseler, M., Kurtzberg, J., Haynes, B. F., and Fauci, A. S.,
23. Healey, D., Dianda, L., Moore, J. P., McDougal, J. S., Moore, M. J.,Proc. Natl. Acad. Sci. USA 87, 7727–7731 (1990).
Estress, P., Buck, D., Kwong, P. D., Beverley, P. C. L., and Satten-8. Valentin, H., Nugeyre, M.-T., Vuillier, F., Boumsell, L., Schmid, M.,
tau, Q. J., J. Exp. Med. 172, 1233– 1242 (1990).Barre´-Sinoussi, F., and Pereira, R., J. Virol. 68, 3041–3050 (1994).
24. De Mareuil, J., Brichacek, B., Salaun, D., Chermann, J.-C., and9. Mu¨ller, J. G., Krenn, V., Schindler, C., Czub, S., Stahl-Hennig, C.,
Hirsch, I., J. Virol. 66, 6797–6801 (1992).Coulibaly, C., Hunsmann, G., Kneitz, C., Kerbau, T., Rethwilm,
25. Spire, B., Hirsch, I., Neuveut, C., Sire, J., and Chermann, J.-C., Virol-A., terMeulen, V., and Mu¨ller-Hermelink, H. K., Am. J. Pathol. 143,
ogy 177, 756–758 (1990).699– 713 (1993).
26. Signoret, N., Poignard, P., Blanc, D., and Sattentau, Q. J., Trends10. Aldrovandi, G. M., Feuer, G., Gao, L., Jamieson, B., Kristeva, M.,
Microbiol. 1, 328– 333 (1993).Chen, I. S. Y., and Zack, J. A., Nature 363, 732– 736 (1993).
27. Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M.,11. Numazaki, K., Bai, Q. X., Goldman, H., Wong, I., Spira, B., and Wain-
Di Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B.,berg, M. A., Clin. Immunol. Immunopathol. 51, 185– 195 (1989).
Peiper, S. C., Schall, T. J., Littman, D. R., and Landau, N. R., Na-12. Stanley, S. K., McCune, J. M., Kaneshima, H., Justement, J. S., Sulli-
ture 381, 661– 666 (1996).van, M., Boone, E., Baseler, M., Adelsberger, J., Bonyhadi, M.,
28. Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Naga-Orenstein, J., Fox, C. H., and Fauci, A. S., J. Exp. Med. 178, 1151–
shima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P.,1163 (1993).
and Paxton, W. A., Nature 381, 667–673 (1996).13. Autran, B., Guiet, P., Raphael, M., Grandadam, M., Agut, H., Can-
29. Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E.,dotti, D., Grenot, P., Puech, F., Debre´, P., and Cesbron, J.-Y.,
Murphy, P. M., and Berger, E. A., Science 272, 1955– 1958AIDS 10, 717–727 (1996).
(1996).14. Dalloul, A. H., Arock, M., Fourcade, C., Hatzfeld, A., Bertho, J.-M.,
30. Hirsch, I., Salaun, D., Brichacek, B., and Chermann, J.-C., VirologyDebre, P., and Mossalayi, M. D., Blood 77, 69 – 74 (1991).
186, 647– 654 (1992).
15. Gay-Bellile, V., Boumsell, L., Caillou, B., and Bernard, A., Thymus
31. Heinzinger, N. K., Bukrinsky, M. I., Heggerty, S. A., Ragland, A. M.,
8, 201–223 (1986).
Kewalramani, V., Lee, M.-A., Gendelman, H. E., Ratner, L., Ste-
16. Rey, F., Donker, G., Hirsch, I., and Chermann, J.-C., Virology 181, venson, M., and Emerman, M., Proc. Natl. Acad. Sci. USA 91,
165– 171 (1991). 7311–7315 (1994).
17. Brichacek, B., Derderian, C., Chermann, J.-C., and Hirsch, I., Cancer 32. Jamieson, B. D., Aldrovandi, G. M., Planelles, V., Jowett, J. B. M.,
Lett. 63, 23 –31 (1992). Gao, L., Bloch, L. M., Chen, I. S. Y., and Zack, J. A., J. Virol. 68,
18. Wain-Hobson, S., Vartanian, J.-P., Henry, M., Chencier, N., Cheynier, 3478–3485 (1994).
R., Delassus, S., Pedroza Martins, L., Sala, M., Nugeyre, M.-T., 33. Ritter, M. A., and Boyd, R. L., Immunol. Today 14, 462–469 (1993).
Gue´tard, D., Klatzmann, D., Gluckman, J.-C., Rozenbaum, W., 34. van Ewijk, W., Shores, E. W., and Singer, A., Immunol. Today 15,
Barre´-Sinoussi, F., and Montagnier, L., Science 252, 961– 965 214–217 (1994).
(1991). 35. Rey, M. A., Spire, B., Dormont, D., Barre´-Sinoussi, F., Montagnier,
19. Yahi, N., Fantini, J., and Chermann, J.-C., AIDS 6, 335–336 (1992). L., and Chermann, J.-C., Biochem. Biophys. Res. Commun. 121,
20. Fantini, J., Yahi, N., and Chermann, J.-C., Proc. Natl. Acad. Sci. USA 126–133 (1984).
88, 9297 –9301 (1991). 36. David, F. J. E., Autran, B., Tran, H. C., Menu, E., Raphael, M., Debre´,
21. Kabat, D., Kozak, S. L., Wehrly, K., and Chesebro, B., J. Virol. 68, P., Hsi, B. L., Wegman, T. G., Barre´-Sinoussi, F., and Chaouat,
G., Clin. Exp. Immunol. 88, 10– 16 (1992).2570– 2577 (1994).
AID VY 8211 / 6a21$$$462 10-18-96 13:02:34 vira AP: Virology
